Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306823 | 1.00 | KDM1A (0.46) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL2306821 | 1.00 | KDM1A (0.46) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL2310415 | 0.93 | BTK (0.48) | KDM1AMAOBBTKGAA | |
| SCHEMBL2310421 | 0.93 | BTK (0.48) | KDM1AMAOBBTKGAA | |
| SCHEMBL2310417 | 0.93 | BTK (0.48) | KDM1AMAOBBTKGAA | |
| SCHEMBL1991622 | 0.88 | GAA (0.48) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL18926195 | 0.84 | GAA (0.44) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL30191398 | 0.84 | GAA (0.44) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL28626264 | 0.84 | KDM1A (0.51) | KDM1AMAOBBTKGAACTSK | |
| SCHEMBL28626267 | 0.84 | KDM1A (0.51) | KDM1AMAOBBTKGAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2531190-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | GLRA1, GRIA1, GLRA2 | KDM1A 2201/4885MAOB 1609/4885BTK 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.